Takeda Receives Japanese Regulatory Approval for HYQVIA® in Primary and Secondary Immunodeficiency Disorders

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) announced that Takeda received regulatory approval for HYQVIA® [Immune Globulin Infusion 10%...

December 31, 2024 | Tuesday | News
Sangamo Therapeutics Regains Rights to Giroctocogene Fitelparvovec Following Pfizer's Decision to End Collaboration

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced it will regain development and commercialization rights to giroctocog...

December 31, 2024 | Tuesday | News
Novartis Announces Positive Phase III STEER Study Results for OAV101 IT in Spinal Muscular Atrophy Type 2 Patients

Novartis announced positive topline results from the Phase III STEER study. This pivotal study assessed the efficacy and safety of investigational intrathe...

December 31, 2024 | Tuesday | News
BMS Gains FDA Approval for Opdivo Qvantig, First Subcutaneous PD-1 Inhibitor with Three-Minute Administration

-Bristol Myers Squibb (NYSE: BMY)  announced that the U.S. Food and Drug Administration (FDA) granted approval for Opdivo Qvantig™&nbs...

December 30, 2024 | Monday | News
IDEAYA Biosciences Acquires Global Rights to SHR-4849 DLL3-Targeting ADC in $1 Billion Agreement with Hengrui Pharma

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, an...

December 30, 2024 | Monday | News
Hoth Therapeutics Secures Exclusive Patent License from VA and Emory University to Tackle Obesity and Related Diseases

Hoth Therapeutics Enters Exclusive Patent License Agreement with VA and Emory University Hoth Also Expands Its' Intellectual Property to Further Its' Ma...

December 27, 2024 | Friday | News
AusperBio Therapeutics Secures $73M Series B Funding to Advance Targeted Therapies for Chronic Hepatitis B

AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a privately held clinical-stage biotechnology company dedicated to ...

December 27, 2024 | Friday | News
Bristol Myers Squibb’s Sotyktu Achieves Key Phase 3 Success in Psoriatic Arthritis, Demonstrating Significant Efficacy

 Bristol Myers Squibb (NYSE: BMY) announced results from POETYK PsA-1 (IM011-054) and POETYK PsA-2 (IM011-055), the pivotal Phase 3 trials evalua...

December 24, 2024 | Tuesday | News
CStone Pharmaceuticals Submits Clinical Trial Application for CS2009, a Tri-Specific Antibody Targeting PD-1, VEGF, and CTLA-4 for Solid Tumors

CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therap...

December 23, 2024 | Monday | News
FDA Approves Zepbound® (Tirzepatide) as First Treatment for Moderate-to-Severe Obstructive Sleep Apnea in Adults with Obesity

Eli Lilly and Company (NYSE: LLY) announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the fir...

December 21, 2024 | Saturday | News
FDA Approves BRAFTOVI® Combination Therapy for First-Line Treatment of Metastatic Colorectal Cancer with BRAF V600E Mutation

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with cetuxi...

December 21, 2024 | Saturday | News
Regeneron Announces Positive Phase 2 Results for Factor XI Antibodies REGN7508 and REGN9933 in Preventing Venous Thromboembolism

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced positive Phase 2 results for two novel monoclonal antibodies targeting distinct domains of Fa...

December 20, 2024 | Friday | News
Shuttle Pharmaceuticals and UCSF Collaborate in the U.S. to Advance Theranostic Innovations for Prostate Cancer

Shuttle Pharmaceuticals Holdings, Inc.  a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer ...

December 20, 2024 | Friday | News
European Commission Grants Orphan Medicinal Product Designation to Mitapivat for Sickle Cell Disease

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases...

December 19, 2024 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close